Current Gene Therapy's 2026 Journal Metrics Score is 3.8, ranking Q1 in Genetics. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 2.01.
Middle 50%: 84–139 days
99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025
Current Gene Therapy accepts papers a median of 118 days after submission, including peer review and revisions. That is slower than 55% of comparable journals with PubMed timing data.
No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
26 of 188 works · same type, year & subfield
0 works · same type, year & subfield
Below field-year expectation
of 632 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.88, so its typical recent paper runs about 12% below its field benchmark.
13.8% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2016–2025
188 OpenAlex works · 2021–2024
OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.
Select a MeSH signal to see how much Current Gene Therapy publishes on it, from PubMed counts for the last five complete years.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Genetics | Q1 |
| Molecular Biology | Q2 |
Yes. A Q1 journal by citation data
Yes. By citation data, Current Gene Therapy is a strong journal: it is Q1 in Genetics and ranks #834 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 23%). Current Gene Therapy's 2026 Journal Metrics Score is 3.8. Recent papers took a median of 118 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Genetics and Molecular Biology, so check that your topic fits its scope.
Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
OpenAlex classifies Current Gene Therapy's papers in subfields including Genetics and Molecular Biology. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.
Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.
Current Gene Therapy homepage ↗Use the submit link in Current Gene Therapy's author guidelines; Bentham Science Publishers runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.
OpenAlex has no article processing charge on record. Check the journal website for page charges or an optional open-access fee.
Recent accepted papers took a median of 118 days from submission to acceptance, including revisions (PubMed dates). Current Gene Therapy does not publish an acceptance rate.
New on PubMed
Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.
See a demo:GLP-1CRISPRLong COVID
Reviewer Two · coming soon
An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.
See what the report coversYes. By citation data, Current Gene Therapy is a strong journal: it is Q1 in Genetics and ranks #834 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 23%). Current Gene Therapy's 2026 Journal Metrics Score is 3.8. Recent papers took a median of 118 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Genetics and Molecular Biology, so check that your topic fits its scope.
Current Gene Therapy's 2026 Journal Metrics Score is 3.8, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
We have not found an official acceptance rate published by Current Gene Therapy or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 118 days from submission to acceptance. To judge selectivity, compare Current Gene Therapy's quartile and score with similar journals, or ask the editorial office.
Current Gene Therapy's best quartile is Q1. By OpenAlex subfield: Q1 in Genetics; Q2 in Molecular Biology. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Current Gene Therapy will not match this score exactly. Compare journals using one source at a time.
Current Gene Therapy accepts papers a median of 118 days after submission across 99 recent PubMed records with both dates; the middle half took 84–139 days. This includes peer review, editorial handling, and revisions.
PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Current Gene Therapy, which includes peer review and revisions, has a median of 118 days. For the time to a first decision, check the journal's own website.
Current Gene Therapy's median of 118 days from submission to acceptance is slower than 55% of comparable journals with PubMed timing data.
Comparable journals include Molecular Therapy, Molecular Therapy Methods & Clinical Development, Gene Therapy, and Human Gene Therapy. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.
Submit online through the link in Current Gene Therapy's author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 118 days from submission to acceptance in recent PubMed records.